Fuzzy OS Benefits in Drug Labels; Zantac Suit Dismissed; Cancer Deaths Drop For Now

The overall survival benefits associated with use of many newly approved cancer drugs are often not clearly communicated in drug labels. (JAMA Internal Medicine)

A reduced-dose CT scan of 0.3 mSv can safely be used to detect lung nodules in children with cancer without sacrificing diagnostic accuracy. (American Journal of Roentgenology)

A federal judge has dismissed claims against dozens of generic manufacturers and pharmacies regarding allegations that the Zantac heartburn pill contains a cancer-causing compound. (Bloomberg Law)

Among common cancers with declining death rates, lung cancer and melanoma are decreasing the most, contributing to the overall continued decline in U.S. cancer death rates as shown in the latest Annual Report to the Nation on the Status of Cancer.

But screening delays associated with the COVID-19 pandemic could result in almost 2,500 excess breast cancer deaths over the next decade. (Journal of the National Cancer Institute)

The International Association for the Study of Lung Cancer (IASLC) has published a new consensus statement on the use of liquid biopsy for advanced non-small cell lung cancer. (Journal of Thoracic Oncology)

Researchers at Johns Hopkins University have identified a specialized protein that appears to prevent tumor cells from entering the bloodstream and circulating to different parts of the body. (Science Advances)

Seagen and Astellas Pharma announced that the FDA has granted regular approval and an expanded indication for enfortumab vedotin-ejfv (Padcev) for treating patients with locally advanced or metastatic urothelial cancer.

The FDA chastised Amgen for misbranding its biological product pegfilgrastim (Neulasta) by including false or misleading promotional information about its benefit.

The Society for Immunotherapy of Cancer has published a clinical practice guideline on managing immune checkpoint inhibitor-related adverse events. (Journal for ImmunoTherapy of Cancer)

The remainder of 2021 is expected to be “pivotal” for the field of personalized neoantigen immuno-oncology therapeutics, according to the data analytics company GlobalData.

Researchers at the University of California, Davis, are exploring whether the use of the spice turmeric can reduce joint pain in breast cancer patients being treated with anti-estrogen drugs.

One-quarter of lung cancer deaths could be avoided in high-risk populations with targeted lung cancer screening, according to a new report from the Lung Ambition Alliance, a partnership of AstraZeneca, IASLC, Guardant Health, and the Global Lung Cancer Coalition.